Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074833 | 0.79 | PTGES (0.49) | PTGESEGFRMAPT | |
| SCHEMBL202476 | 0.79 | PTGES (0.49) | PTGESEGFRMAPT | |
| SCHEMBL202480 | 0.78 | MEN1 (0.45) | ALDH1A1MAPTNPC1MAPK1RAB9A | |
| SCHEMBL19890459 | 0.75 | PTGES (0.46) | PTGESSMN1; SMN2TNF | |
| SCHEMBL31424455 | 0.75 | PTGES (0.51) | PTGESEGFRMAPT | |
| SCHEMBL30583451 | 0.73 | TSHR (0.37) | PTGESEGFRALDH1A1S1PR4TSHR | |
| SCHEMBL26620010 | 0.73 | PTGES (0.49) | PTGESEGFRALDH1A1MAPT | |
| SCHEMBL842126 | 0.73 | TSHR (0.37) | PTGESEGFRALDH1A1S1PR4TSHR | |
| SCHEMBL1490598 | 0.73 | PTGES (0.49) | PTGESEGFRALDH1A1MAPTMAPK1 | |
| SCHEMBL30074880 | 0.73 | PTGES (0.49) | PTGESEGFRALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | PTGES 181/4885EGFR 2824/4885ALDH1A1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.